Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of PledOx Added to mFOLFOX6 to Prevent Chemotherapy-Induced Peripheral Neuropathy in Adjuvant Colorectal Cancer
2017-004707-43Phase 3Completed
- Sponsor
- Egetis Therapeutics
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing PledOx + mFOLFOX6 with Placebo + mFOLFOX6 (2 arms). Started Mar 2018; status: completed.
02
Drugs
calmangafodipir
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on 2017-004707-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004707-43.